

Evaluating the accuracy of APRI and FIB-4 scores in chronic HBV-related liver fibrosis: A literature review

Willandra Fitriyanri Ghaniyya ¹, Ira Humairah ^{2,*} and Ulfa Kholili ³

¹ Medical Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60131, Indonesia.

² Department of Physiology and Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60131, Indonesia.

³ Department of Internal Medicine, Dr. Soetomo General Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60131, Indonesia.

World Journal of Advanced Research and Reviews, 2024, 24(03), 2680-2684

Publication history: Received on 12 November 2024; revised on 26 December 2024; accepted on 28 December 2024

Article DOI: <https://doi.org/10.30574/wjarr.2024.24.3.3937>

Abstract

Chronic hepatitis B virus (HBV) infection poses significant risks to liver health, often progressing to complications such as fibrosis, cirrhosis, and hepatocellular carcinoma. Accurate assessment of liver fibrosis is essential for guiding treatment decisions and improving patient outcomes. Non-invasive scoring systems like the AST to Platelet Ratio Index (APRI) and the Fibrosis Index Based on 4 Factors (FIB-4) have emerged as reliable alternatives to invasive liver biopsy. These tools utilize readily available biomarkers to classify patients based on fibrosis severity, supporting early intervention and reducing the risks associated with traditional diagnostic methods.

This review evaluates the diagnostic performance of APRI and FIB-4 in chronic HBV-related liver fibrosis. Studies indicate that while APRI is valued for its simplicity, FIB-4 demonstrates superior sensitivity and specificity, particularly in older populations. Both scores show strong correlations with histological findings and serve as effective tools for diagnosing significant fibrosis and cirrhosis. However, factors such as liver inflammation, comorbidities, and variable fibrosis distribution can influence their accuracy, highlighting the need for careful interpretation.

Comparison with advanced methods like FibroScan® underscores the limitations of biochemical indices alone and the importance of combining multiple diagnostic approaches. Future research should focus on longitudinal studies and algorithm optimization to enhance the utility of these non-invasive tools. Integrating APRI and FIB-4 into clinical practice offers a cost-effective and accessible strategy for managing chronic HBV-related liver fibrosis, ultimately improving patient care and outcomes.

Keywords: Chronic HBV; Liver fibrosis; APRI score; FIB-4 index; Non-invasive diagnostics

1. Introduction

In 2019, chronic HBV infection affected an estimated 4.1% of the global population, or about 316 million people (range: 284–351 million).⁸ Chronic hepatitis B virus (HBV) infection poses serious risks to liver health, often resulting in complications like liver fibrosis, cirrhosis, and liver cancer. Persistent inflammation caused by HBV replication leads to ongoing cell damage and fibrosis, where scar tissue builds up due to injury. Identifying the stage of liver fibrosis is critical, as non-invasive tools like APRI and FIB-4 scores help categorize patients based on their risk, guiding appropriate treatment decisions.³ The correlation between HBV severity and liver stiffness measurements is critical for tailoring patient management, ultimately improving outcomes in chronic HBV populations.

* Corresponding author: Ira Humairah

Assessing the level of liver fibrosis in patients with chronic hepatitis B (HBV) is essential for improving patient care and tailoring treatment plans. Accurate evaluation helps classify patients based on their risk of developing cirrhosis and other liver complications. Non-invasive tools like the APRI and FIB-4 scores offer simple and accessible ways to measure liver fibrosis, minimizing the need for invasive procedures such as liver biopsy, which can carry certain risks.³ Many individuals with chronic liver diseases show no symptoms, have normal physical exams, and present with non-specific biological abnormalities, making it difficult to identify those at risk of developing advanced fibrosis.⁹ These evaluations play an important role in clinical decisions, such as starting antiviral therapy, which greatly affects long-term outcomes. Research shows that identifying significant fibrosis early can lead to better survival rates and improved quality of life for HBV patients, emphasizing the need for regular liver health monitoring.¹ Integrating reliable fibrosis assessment tools into routine care is essential for enhancing patient prognosis in chronic HBV management.

Since 1991, non-invasive liver fibrosis tests have advanced, with APRI and FIB-4 standing out as the most promising and widely studied options.⁸ The APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis Index Based on 4 Factors) scores have become important non-invasive tools for evaluating liver fibrosis, especially in chronic HBV-related conditions. By using readily available biomarkers from routine blood tests, these scores estimate liver fibrosis levels without requiring invasive biopsies, which come with risks and potential complications. Recent studies highlight that these tests offer valuable clinical insights, improving patient care and enhancing the efficiency of disease management.⁴ Furthermore, tools such as the FIB-4 score have demonstrated a strong correlation with liver stiffness measurements, which are essential for evaluating the severity of the disease.¹ Integrating these scores into clinical practice could significantly enhance early detection and intervention strategies, ultimately improving patient outcomes in chronic HBV-related liver fibrosis.

2. Understanding APRI and FIB-4 Scores

The utility of the APRI and FIB-4 scores in assessing liver fibrosis in chronic HBV infection has garnered increasing attention in clinical diagnostics. Both scoring systems serve as non-invasive tools that enable physicians to estimate the degree of hepatic fibrosis, thus facilitating timely interventions and improving patient outcomes. The FIB-4 score is calculated using age, AST, ALT, and platelet count, effectively integrating patient demographics with biochemical markers to provide a comprehensive risk assessment. In contrast, APRI relies on AST and platelet counts to yield results, making it simpler yet potentially less sensitive in detecting moderate fibrosis.¹ Notably, studies have demonstrated that both scores correlate well with invasive biopsy results.

2.1. Definition and calculation of APRI score

Liver fibrosis assessment is critical in managing chronic hepatitis B virus (HBV) infections, where the Aspartate Aminotransferase to Platelet Ratio Index (APRI) score serves as a pivotal non-invasive tool. This score is calculated by dividing the patient's AST level, measured in U/L, by the upper limit of normal AST, and then multiplying it by the ratio of the platelet count in $10^9/L$. Specifically, $APRI > 0.7$ suggests significant fibrosis, and > 1.0 predicts cirrhosis. Its utility lies in providing a practical method for identifying patients at higher risk for advanced liver disease without the need for liver biopsy, as highlighted in recent studies.¹⁴ Non-invasive tests are increasingly recognized for their accuracy and reliability, making their use crucial in clinical practice for tracking fibrosis progression in HBV. Tools like APRI play a key role in supporting effective treatment plans and strategies.⁴

2.2. Definition and calculation of FIB-4 score

The FIB-4 score is an important non-invasive tool for evaluating liver fibrosis, especially in patients with chronic hepatitis B (HBV). This scoring system combines age, aspartate aminotransferase (AST), platelet count, and alanine aminotransferase (ALT) in a simple formula, allowing doctors to estimate fibrosis levels without needing invasive biopsies. The calculation involves multiplying the age by the AST value and dividing by the product of the platelet count and the square root of the ALT value. As fibrosis advances, the FIB-4 score has been shown to strongly correlate with histological findings, making it a reliable measure for clinical use. Studies have found that higher FIB-4 scores are associated with greater fibrosis risk, helping guide treatment decisions and monitoring strategies in chronic HBV cases.³

2.3. Comparison of APRI and FIB-4 in clinical practice

In clinical settings, the decision to use either APRI (AST to Platelet Ratio Index) or FIB-4 (Fibrosis Index Based on 4 Factors) depends on factors like accuracy, simplicity, and patient characteristics. Both scores offer non-invasive ways to assess liver fibrosis in chronic HBV patients, reducing the need for liver biopsy. APRI is valued for its straightforward calculation using standard lab tests, while FIB-4 includes age as a factor, making it more sensitive in older patients who are at higher risk for liver disease.¹

3. Clinical Relevance of Liver Fibrosis Assessment

Effectively assessing liver fibrosis is essential for managing chronic HBV-related liver disease, as it impacts both treatment choices and patient outcomes. Non-invasive tools like APRI (AST to Platelet Ratio Index) and FIB-4 offer clinicians reliable ways to evaluate liver health, avoiding the risks and errors associated with liver biopsy.⁵ In clinical practice, choosing between APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis Index Based on 4 Factors) depends on factors like accuracy, ease of use, and patient details. Both scores provide non-invasive ways to check liver fibrosis in people with chronic HBV, avoiding the need for a liver biopsy. APRI is simple to calculate using basic lab tests, while FIB-4 includes age, which makes it more useful for older patients who are more likely to have liver problems.¹

3.1. Role of liver fibrosis in disease progression and management

Understanding liver fibrosis is important for tracking how chronic HBV progresses and managing its risks. As fibrosis gets worse, the chances of health problems and death increase, making early detection and treatment very important. Simple tests like APRI and FIB-4 help doctors estimate how severe fibrosis is without needing invasive procedures like a liver biopsy.² Moreover, the integration of imaging techniques and scoring systems provides an avenue for better monitoring and can guide therapeutic decisions, especially in aging populations at heightened risk for post-hepatectomy liver failure.¹ By systematically identifying fibrotic progression, healthcare providers can more effectively prioritize interventions that mitigate the long-term complications of hepatic disease, thereby enhancing the overall quality of care for patients with chronic HBV.

3.2. Implications of accurate fibrosis staging on treatment decisions

Accurately determining the stage of liver fibrosis is crucial for making informed treatment decisions in patients with chronic HBV. Proper evaluation allows for personalized treatment plans that can greatly improve patient outcomes, as incorrect staging may result in unsuitable interventions. For example, patients with mild fibrosis may benefit more from lifestyle changes and regular monitoring rather than aggressive antiviral therapy. On the other hand, those with advanced fibrosis require immediate treatment to reduce the risk of complications such as cirrhosis and liver cancer. Using tools like APRI and FIB-4 enhances diagnostic precision, ensuring patients are correctly categorized and receive the most appropriate care.³

3.3. Limitations of liver biopsy as a gold standard for fibrosis assessment

Liver biopsy is widely considered the gold standard for evaluating fibrosis, but it has several drawbacks that can affect diagnostic accuracy in chronic HBV-related liver disease. Its invasive nature involves risks like bleeding, infection, and discomfort, which can discourage patients from undergoing the procedure. Moreover, because the biopsy only samples a small portion of the liver, it may result in sampling errors and misclassification of fibrosis stages. This issue is especially significant in conditions with uneven fibrosis distribution, such as chronic hepatitis delta, where non-invasive markers have been shown to be less reliable than liver stiffness measurements for assessing fibrosis stages.⁶

4. Evaluating the Accuracy of APRI and FIB-4 Scores

A detailed analysis of APRI and FIB-4 scores highlights their effectiveness in categorizing patients with chronic HBV-related liver fibrosis. As non-invasive alternatives to liver biopsy, these tools are crucial for patients at risk of disease progression. Research indicates that FIB-4, which includes patient age along with biochemical markers, may provide a more comprehensive assessment of fibrosis severity than APRI, offering a better reflection of liver physiology.¹

4.1. Sensitivity and specificity of APRI and FIB-4 in diagnosing liver fibrosis

Diagnostic Tools like the AST to Platelet Ratio Index (APRI) and the Fibrosis Index Based on 4 Factors (FIB-4) are useful for evaluating liver fibrosis, especially in patients with chronic hepatitis B (HBV). Researchers continue to study how well these scoring systems perform in terms of sensitivity and specificity, given their influence on clinical decisions. While both APRI and FIB-4 show good sensitivity, their specificity often depends on the stage of fibrosis being assessed. For instance, ROC curve analysis suggests that FIB-4 might provide better specificity than APRI for certain patient groups. However, factors like liver inflammation and fat deposits can affect their accuracy, making careful use of these scores essential. This highlights the need to combine non-invasive tests with other diagnostic methods to improve patient care and ensure proper treatment.²

The APRI score has moderate accuracy. With a specificity of 79% and a sensitivity of 34% at a 0.408 cut-off, it is better at confirming fibrosis than ruling it out, making it useful in resource-limited settings.¹⁰ To detect progressing fibrosis

and cirrhosis, APRI cut-off values above 1.5 and 2 are recommended, with ROC areas of 0.80 and 0.89.¹¹ FIB-4 score effectively rules out advanced fibrosis at a 1.45 cut-off, with sensitivity of 70–92%, specificity of 64–75%, and NPV of 52–95%. It outperforms other non-invasive methods in sensitivity and NPV, making it a reliable alternative to liver biopsy.¹² FIB-4 performs similarly to APRI, with an AUC of 0.753 (95% CI: 0.711–0.795, $p < 0.0001$) for significant fibrosis ($\geq F2$). While both tests are effective for diagnosing fibrosis, FIB-4 consistently shows a higher AUROC than APRI, making it considered better than APRI.¹³ Ultimately, the integration of both APRI and FIB-4 within clinical workflows may optimize patient evaluations, allowing for a more nuanced approach to managing chronic HBV-related liver fibrosis

4.2. Factors influencing the accuracy of these scores in HBV patients

The accuracy of APRI and FIB-4 scores in chronic HBV patients can be affected by several factors. One important factor is the liver's histological condition, which influences biomarker levels like AST and platelet counts, key elements of these scores. Changes in liver inflammation and regeneration can cause fluctuations that may not accurately reflect the actual stage of fibrosis.² Combining imaging methods with scoring systems offers a better way to monitor liver health and make treatment decisions, particularly for older patients who are at higher risk of liver failure after surgery.¹ Thus, when interpreting FIB-4 and APRI scores, it is essential to consider these multifaceted influences to enhance diagnostic precision and patient management strategies.

4.3. Comparison of APRI and FIB-4 with other non-invasive methods

In the discussion about the effectiveness of non-invasive methods for detecting liver fibrosis, comparing APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis Index Based on 4 Factors) with other tools highlights important details. Both APRI and FIB-4 have shown good results in identifying fibrosis in patients with chronic HBV, but their reliability needs to be compared with other non-invasive methods like FibroScan® and imaging techniques. APRI stands out for being simple and easy to use, while research suggests that FIB-4 might be more accurate because it includes age as a factor, making it particularly useful for older patients.¹ Advanced techniques such as FibroScan® offer direct measurements of liver stiffness, providing more accurate evaluations and underscoring the limitations of relying solely on biochemical markers. This emphasizes the importance of combining multiple diagnostic methods for better validation in assessing liver fibrosis.³ Integrating these diverse assessment tools will ultimately enhance diagnostic accuracy and patient outcomes.

5. Conclusion

APRI and FIB-4 scores have become key non-invasive methods for evaluating liver fibrosis, especially in patients with chronic HBV. Research has shown that these tools are effective in identifying significant fibrosis and cirrhosis, offering reliable, though not perfect, assessments. Notably, the FIB-4 score often matches or outperforms APRI in distinguishing between fibrosis stages. Studies also highlight the importance of understanding underlying conditions, including co-infections like HIV, for accurate interpretation of these scores.³

5.1. Implications for clinical practice and patient management

Using non-invasive liver tests like APRI and FIB-4 scores in clinical practice has important benefits for managing patients, especially those with chronic HBV-related liver fibrosis. These tools help with early diagnosis and identifying patients who need closer monitoring or treatment, without relying on invasive procedures like liver biopsy. This approach not only improves patient safety by avoiding biopsy risks but also helps healthcare systems use resources more efficiently. For example, FIB-4, which includes age and basic lab data, has been shown to reliably predict liver conditions, including the risk of liver failure after surgery and advanced fibrosis stages.¹

5.2. Recommendations for future research on liver fibrosis assessment in HBV patients

Future research should focus on conducting longitudinal studies to evaluate changes in liver stiffness over time across diverse demographic groups, providing deeper insights into the ability of these assessments to accurately monitor disease progression. Additionally, examining the biochemical markers that contribute to FIB-4 and APRI scores could support the development of more precise algorithms tailored to the unique profiles of HBV patients

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

- [1] Marasco, G., Colecchia, A., Milandri, M., Rossini, B., Alemanni, L. V., Dajti, E., Ravaioli, F., Renzulli, M., Golfieri, R., & Festi, D. (2020). Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly. *Hepatoma Research*, 2020. <https://doi.org/10.20517/2394-5079.2019.54>
- [2] Parikh, P., Ryan, J. D., & Tsochatzis, E. A. (2017). Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. *Annals of translational medicine*, 5(3), 40. <https://doi.org/10.21037/atm.2017.01.28>
- [3] Crossan, C., Tsochatzis, E. A., Longworth, L., Gurusamy, K., Davidson, B., Rodríguez-Perálvarez, M., Mantzoukis, K., O'Brien, J., Thalassinou, E., Papastergiou, V., & Burroughs, A. (2015). Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. *Health technology assessment (Winchester, England)*, 19(9), 1-vi. <https://doi.org/10.3310/hta19090>
- [4] Roade, L., Riveiro-Barciela, M., Palom, A., Rodríguez-Frías, F., Bes, M., Rando, A., Salcedo, M. T., Casillas, R., Vargas-Accarino, E., Taberner, D., Sauleda, S., Esteban, R., & Buti, M. (2022). ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype. *Journal of clinical and translational hepatology*, 10(6), 1068–1076. <https://doi.org/10.14218/JCTH.2022.00068>
- [5] Valva, P., Ríos, D. A., De Matteo, E., & Preciado, M. V. (2016). Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. *World journal of gastroenterology*, 22(4), 1367–1381. <https://doi.org/10.3748/wjg.v22.i4.1367>
- [6] Gidaagaya, S., Dorj, S., Jamsranjav, S., Dungubat, E., Batmunkh, M., & Namdag, B. (2019). Measurement of Liver Fibrosis in Chronic Hepatitis D: Comparison of Invasive and Non-Invasive Methods. *Central Asian Journal of Medical Sciences*, 5(1), 64–76. <https://doi.org/10.24079/cajms.2019.03.009>
- [7] Xu, X. Y., Wang, W. S., Zhang, Q. M., Li, J. L., Sun, J. B., Qin, T. T., & Liu, H. B. (2019). Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. *World journal of clinical cases*, 7(15), 2022–2037. <https://doi.org/10.12998/wjcc.v7.i15.2022>
- [8] GBD 2019 Hepatitis B Collaborators (2022). Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *The lancet. Gastroenterology & hepatology*, 7(9), 796–829. [https://doi.org/10.1016/S2468-1253\(22\)00124-8](https://doi.org/10.1016/S2468-1253(22)00124-8)
- [9] Canivet, C. M., & Boursier, J. (2022). Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?. *Diagnostics (Basel, Switzerland)*, 13(1), 91. <https://doi.org/10.3390/diagnostics13010091>
- [10] Gür-Altunay, D., & Yürük-Atasoy, P. (2023). How Successful Are APRI and FIB-4 Scores in Predicting Liver Fibrosis in Chronic Hepatitis B Patients?. *Infectious diseases & clinical microbiology*, 5(4), 332–340. <https://doi.org/10.36519/idcm.2023.276>
- [11] Loaeza-del-Castillo, A., Paz-Pineda, F., Oviedo-Cárdenas, E., Sánchez-Avila, F., & Vargas-Vorácková, F. (2008). AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. *Annals of hepatology*, 7(4), 350–357.
- [12] Xu, X. L., Jiang, L. S., Wu, C. S., Pan, L. Y., Lou, Z. Q., Peng, C. T., Dong, Y., & Ruan, B. (2022). The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?. *Journal of the Formosan Medical Association = Taiwan yi zhi*, 121(2), 454–466. <https://doi.org/10.1016/j.jfma.2021.07.013>
- [13] Das, A. K. (2023). CORRELATION OF FIB-4 AND APRI SCORE WITH FIBRO SCAN SCORE TO PREDICT FIBROSIS IN OBESE TYPE-2 DIABETIC PATIENTS. <https://doi.org/10.51168/sjhrafrica.v4i12.761>
- [14] Oikonomou, T., Chrysavgis, L., Kiapidou, S., Adamantou, M., Parastatidou, D., Papatheodoridis, G. V., Goulis, I., & Cholongitas, E. (2023). Aspartate aminotransferase-to-platelet ratio index can predict the outcome in patients with stable decompensated cirrhosis. *Annals of gastroenterology*, 36(4), 442–448. <https://doi.org/10.20524/aog.2023.0800>